The Philippine Health Insurance Corporation (PhilHealth) endorsed new enhanced benefit packages to the agency’s board. The ...
The Philippine Health Insurance Corporation (PhilHealth) endorsed five 'better benefit packages' for heart attacks, rare ...
11.3. The Advisory Committee recommended that avalglucosidase alfa for the treatment of late onset Pompe disease be funded with a medium priority.
The Department of Health (DOH) on Friday, Nov. 15, announced that the Benefits Committee (BenCom) of the Philippine Health ...
Amicus Therapeutics Inc (FOLD) reports a 37% revenue increase and raises full-year guidance, despite ongoing litigation challenges.
Sanofi has added another string to its Pompe disease therapy bow, after getting FDA approval for Nexviazyme, its latest therapy for the rare, inherited disorder. The US regulator has approved ...
In the preceding three months, 8 analysts have released ratings for Amicus Therapeutics FOLD, presenting a wide array of ...
This would be with respect to Pombiliti [cipaglucosidase alfa-atga] + Opfolda [miglustat] having been approved for the treatment of adults with late-onset Pompe Disease. The truth is that there is ...
(AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that AB ...
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...
Their results argue for a change to parity between small-molecule agents and biologics when it comes to Inflation Reduction ...